Join Us as We Discuss the What, Why and How
In 2023, the average cost per claimant for Ozempic® was $5,550, an 18% increase from 2022. Ozempic now ranks as the second highest-paid drug, behind Humira®, according to Unison’s annual book of business report. The number of individuals taking Ozempic increased 135% year-over-year, contributing to the climb in overall healthcare spend*.
According to the CDC, approximately 42% of adult Americans are classified as obese, but this number exceeds 73% when adding in overweight individuals.
Understanding the value of weight loss drugs, potential ROI, treatment plans and wraparound service options are critical as you determine your organizations’ long-term employee benefits strategy.
Watch as our experienced panel from the Cleveland Clinic and Foundational Pharmacy Strategies discuss these important topics.
Presented by
- Dr. Bruce Rogen, MD MPH FAC, Chief Medical Officer, Cleveland Clinic
- Raul J. Rosenthal, MD,FASMBS, Regional Chair, Digestive Disease & Surgical Institute, Department Chair of Bariatric, Metabolic Surgery and General Surgery, Cleveland Clinic
- Kelly Prymicz, Co-Founder and VP of Clinical Strategy, Foundational Pharmacy Strategies
- Christine Johnston, Co-Founder and Pharmacy Practice Leader, Foundational Pharmacy Strategies
Moderated by
- Tom Sigman, Strategic Solutions Leader, Unison Risk Advisors
Webinar On-Demand | Passcode: GLP1med2024!
At Unison Risk Advisors, we create member-driven solutions that help control spend and create quality outcomes. We do this through our Univation Labs team, which is a collaboration of industry experts, academics and clinicians.
*Data source 2022 Unison Risk Advisors book of business.
For more information, contact us here.
Subscribe to Oswald Advisories
Signup